Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rHuEPO for Postoperative Outcome in Pediatric Moyamoya
NCT03882060Unknown
- Sponsor
- Seoul National University Hospital
- Start
- Apr 2019
- Primary completion
- Dec 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, double-blind trial of erythropoietin in Moyamoya disease (2 arms), sponsored by Seoul National University Hospital. Primary endpoint: Postoperative Angiogenesis. Status: unknown.
02
Drugs
erythropoietin
03
Conditions
Moyamoya disease
Beyond the preview
Go deeper on NCT03882060.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03882060.